Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Methotrexate in inflammatory bowel disease: a multicenter retrospective study focused on long-term efficacy and safety. The Madrid experience.

González-Lama Y, Taxonera C, López-Sanromán A, Pérez-Calle JL, Bermejo F, Pajares R, McNicholl AG, Opio V, Mendoza JL, López P, Algaba A, Estelles J, Barbero A, Mendoza J, Maté J, Gisbert JP; Madrid Group for Study of Inflammatory Bowel Diseases (ENICMAD)..

Eur J Gastroenterol Hepatol. 2012 Sep;24(9):1086-91.

PMID:
22713509
2.

Experience with the use of low-dose methotrexate for inflammatory bowel disease.

Soon SY, Ansari A, Yaneza M, Raoof S, Hirst J, Sanderson JD.

Eur J Gastroenterol Hepatol. 2004 Sep;16(9):921-6.

PMID:
15316419
3.

The efficacy of methotrexate for maintaining remission in inflammatory bowel disease.

Fraser AG, Morton D, McGovern D, Travis S, Jewell DP.

Aliment Pharmacol Ther. 2002 Apr;16(4):693-7.

4.

Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.

Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M.

Dig Liver Dis. 2005 Jun;37(6):407-17. Review.

PMID:
15893279
5.

Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study.

Ardizzone S, Bollani S, Manzionna G, Imbesi V, Colombo E, Bianchi Porro G.

Dig Liver Dis. 2003 Sep;35(9):619-27.

PMID:
14563183
6.

Long-term methotrexate for Crohn's disease: safety and efficacy in clinical practice.

Domènech E, Mañosa M, Navarro M, Masnou H, Garcia-Planella E, Zabana Y, Cabré E, Gassull MA.

J Clin Gastroenterol. 2008 Apr;42(4):395-9. doi: 10.1097/MCG.0b013e31802e6875.

PMID:
18277899
7.

Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.

Zabana Y, Domènech E, Mañosa M, Garcia-Planella E, Bernal I, Cabré E, Gassull MA.

Aliment Pharmacol Ther. 2010 Mar;31(5):553-60. doi: 10.1111/j.1365-2036.2009.04206.x. Epub 2009 Nov 30.

8.
9.

The use of methotrexate for treatment of inflammatory bowel disease in clinical practice.

Saibeni S, Bollani S, Losco A, Michielan A, Sostegni R, Devani M, Lupinacci G, Pirola L, Cucino C, Meucci G, Basilisco G, D'Incà R, Bruno S.

Dig Liver Dis. 2012 Feb;44(2):123-7. doi: 10.1016/j.dld.2011.09.015. Epub 2011 Nov 2.

PMID:
22051323
10.

Careful patient selection may improve response rates to infliximab in inflammatory bowel disease.

Pearce CB, Lawrance IC.

J Gastroenterol Hepatol. 2007 Oct;22(10):1671-7.

PMID:
17845695
11.

Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality.

Caspersen S, Elkjaer M, Riis L, Pedersen N, Mortensen C, Jess T, Sarto P, Hansen TS, Wewer V, Bendtsen F, Moesgaard F, Munkholm P; Danish Crohn Colitis Database..

Clin Gastroenterol Hepatol. 2008 Nov;6(11):1212-7; quiz 1176. doi: 10.1016/j.cgh.2008.05.010. Epub 2008 Oct 9.

PMID:
18848503
12.

Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.

Sokol H, Seksik P, Carrat F, Nion-Larmurier I, Vienne A, Beaugerie L, Cosnes J.

Gut. 2010 Oct;59(10):1363-8. doi: 10.1136/gut.2010.212712. Epub 2010 Jun 29.

PMID:
20587545
13.

The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series.

Sandhu A, Alameel T, Dale CH, Levstik M, Chande N.

Aliment Pharmacol Ther. 2012 Jul;36(2):159-65. doi: 10.1111/j.1365-2036.2012.05141.x. Epub 2012 May 23.

14.

Safety and effectiveness of infliximab for inflammatory bowel diseases in clinical practice.

Tursi A, Elisei W, Brandimarte G, Giorgetti G, Penna A, Castrignano V.

Eur Rev Med Pharmacol Sci. 2010 Jan;14(1):47-55.

PMID:
20184089
15.

Inflammatory bowel disease: current therapeutic options.

Domènech E.

Digestion. 2006;73 Suppl 1:67-76. Epub 2006 Feb 8. Review.

PMID:
16498254
16.

Methotrexate as single therapy in Crohn's disease: is its long-term efficacy limited?

Charpignon C, Beau P.

Gastroenterol Clin Biol. 2008 Feb;32(2):153-7. doi: 10.1016/j.gcb.2007.11.011. Epub 2008 Mar 17.

17.

Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response.

González-Lama Y, López-San Román A, Marín-Jiménez I, Casis B, Vera I, Bermejo F, Pérez-Calle JL, Taxonera C, Martínez-Silva F, Menchén L, Martínez-Montiel P, Calvo M, Carneros JA, López P, Mendoza JL, Milicua JM, Huerta A, Sánchez F, Abreu L, López-Palacios N, Maté J, Gisbert JP; Group for the Study of Inflammatory Bowel Diseases from Madrid (ENICMAD)..

Gastroenterol Hepatol. 2008 Aug-Sep;31(7):421-6.

PMID:
18783686
18.

6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease.

Maté-Jiménez J, Hermida C, Cantero-Perona J, Moreno-Otero R.

Eur J Gastroenterol Hepatol. 2000 Nov;12(11):1227-33.

PMID:
11111780
19.

The safety and tolerability of methotrexate for treating patients with Crohn's disease.

Chande N, Abdelgadir I, Gregor J.

J Clin Gastroenterol. 2011 Aug;45(7):599-601. doi: 10.1097/MCG.0b013e3181f593f9. Review.

PMID:
21224737
20.

Oral methotrexate in ulcerative colitis.

Cummings JR, Herrlinger KR, Travis SP, Gorard DA, McIntyre AS, Jewell DP.

Aliment Pharmacol Ther. 2005 Feb 15;21(4):385-9.

Supplemental Content

Support Center